Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lipid nanoparticle delivery promotes cell-type-specific distribution of antisense oligonucleotides in the brain

ABSTRACT: Lipid nanoparticle delivery promotes cell-type-specific distribution of antisense oligonucleotides in the brain

PROVIDER: PRJNA911308 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22692800.fastq.gz	Fastqsanger.gz
	SRR22692801.fastq.gz	Fastqsanger.gz
	SRR22692802.fastq.gz	Fastqsanger.gz
	SRR22692803.fastq.gz	Fastqsanger.gz
	SRR22692804.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 31

Similar Datasets

Lipid nanoparticle delivery promotes cell-type-specific distribution of antisense oligonucleotides in the brain

Project description:Antisense oligonucleotides (ASOs) are being actively investigated as potential therapeutics for a broad range of neurodegenerative diseases. While these small oligonucleotides have been effective in the clinic, many basic questions regarding ASO internalization, trafficking, and modes of enhancing delivery remain. To address these questions, we investigated how lipid nanoparticle (LNP) delivery affects ASO uptake and distribution in the brain. We show that ASOs are internalized and active in central nervous system (CNS) cell types both in vivo and in vitro. While differential cellular activity and polarization states do not affect ASO potency, encapsulating ASOs in LNPs increases ASO activity up to 100-fold in cultured CNS cells. This dramatic increase in efficacy is facilitated by the intracellular trafficking of ASOs away from lysosomes or enhanced ASO uptake, which is cell-type-specific. We assessed the translatability of these results by screening ASO-LNPs in vitro and intracerebroventricularly injecting top performing formulations in mice. ASO-LNP delivery induced a strong ASO-dependent microgliosis response in the brain revealing that LNP encapsulation cannot mask ASO-mediated toxicity. However, LNP-delivered ASOs did not downregulate mRNA levels in bulk tissue due to changes in ASO distribution. While ASOs distribute widely across the brain after bulk injection, ASO-LNPs are preferentially internalized by cells lining the blood vessels and ventricles. Consistent with our findings in cells, ASOs localize to the endolysosomal system following both ASO and ASO-LNP delivery in the brain as determined using immunoelectron microscopy. These data provide valuable insights into how LNPs regulate ASO uptake and distribution in the brain, and support further development of ASO-LNPs for treating CNS disorders.

2023-05-15 | GSE220777 | GEO

Single cell multiomic readouts reveal that cellular heterogeneity impacts lipid nanoparticle-mediated mRNA delivery

Project description:We report the development of a new multiomic nanoparticle delivery system called Single cEll Nanoparticle Transcriptome-sequencing (SENT-seq), which quantifies how dozens of lipid nanoparticles (LNPs) deliver DNA barcodes and mRNA into cells, subsequent protein production, and the transcriptome, with single cell resolution. We show from the sequencing data that cell heterogeneity influences the efficiency with which LNPs deliver mRNA therapies, and identify cell subtypes that exhibit particularly high or low LNP uptake as well as genes associated with those subtypes. These data suggest that cell subsets have distinct responses to LNPs, and that these differential interactions can affect mRNA therapies.

2023-01-23 | GSE186395 | GEO

Therapeutic Delivery of Targeted Nanoparticle Cannabinoid Equivalents

Project description:Therapeutic Delivery of Targeted Nanoparticle Cannabinoid Equivalents

| PRJNA849515 | ENA

Apatite nanoparticle(sCA)-siTIMP1 delivery in NIH3T3

Project description:Apatite nanoparticle(sCA)-siTIMP1 delivery in NIH3T3

| PRJNA526507 | ENA

Targeting Smyd3 by antisense oligonucleotides attenuates liver tumor growth

Project description:We investigated whether pharamacological inhibition of Smyd3 by antisense oligonucleotides (ASOs) can influence diethylnitrosamine (DEN)-induced liver cancer development. Our phenotypic analyses, among others, included gene expression profiling.

2020-06-24 | GSE153077 | GEO

Expression data from dosing four different antisense oligonucleotides in mice II

Project description:We used microarrays to globally profile the gene expression changes observed in liver after 3 days when dosing antisense oligonucleotides in mice

2018-04-30 | GSE100698 | GEO

Expression data from transfection of two different antisense oligonucleotides in HuH7 cells

Project description:We used microarrays to globally profile the gene expression changes observed after 24h when transfecting antisense oligonucleotides in HuH77 cells

2017-04-21 | GSE93245 | GEO

Expression data from transfection of 14 different antisense oligonucleotides in HuH7 cells

Project description:We used microarrays to globally profile the gene expression changes observed after 10h and 24h when transfecting antisense oligonucleotides in HuH7 cells

2017-04-21 | GSE93244 | GEO

Phospholamban Antisense Oligonucleotides Improve Cardiac Function in Murine Cardiomyopathy

Project description:Phospholamban Antisense Oligonucleotides Improve Cardiac Function in Murine Cardiomyopathy

| PRJNA634911 | ENA

Targeting Smyd3 by antisense oligonucleotides attenuates liver tumor growth

Project description:Targeting Smyd3 by antisense oligonucleotides attenuates liver tumor growth

| PRJNA641395 | ENA